Abstracts tagged "hyperuricemia"

Abstract Number: 338 • 2019 ACR/ARP Annual Meeting
Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults
Angelo Gaffo¹, David Calhoun ², Elizabeth Rahn ¹, Suzanne Oparil ², Peng Li ², Tanja Dudenbostel ², David Redden ², Amy Mudano ², Jeffrey Foster ¹, Daniel Feig ², Stephanie Biggers ² and Kenneth Saag ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: The association between serum urate and hypertension continues to be a matter of controversy. Studies in adolescents provided evidence for the efficacy of urate…
Abstract Number: 345 • 2019 ACR/ARP Annual Meeting
Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey
Kyong-Hee Jung¹, Seung Yun Lee ¹, Won Park ¹, Young Ju Suh ¹, Mie Jin Lim ¹, Seong-Ryul Kwon ¹, Joo-Hyun Lee ² and Young Bin Joo ³, ¹Inha University Hospital, Incheon, Republic of Korea, ²Inje University Ilsan Paik Hospital, Goyang, Republic of Korea, ³St. Vincent’s Hospital, Seoul, Republic of Korea
Background/Purpose: The cardiovascular risk of gout is already well known, and the debate over the cardiovascular risk of uric acid lower agents is currently hot.…
Abstract Number: 352 • 2019 ACR/ARP Annual Meeting
Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis
Ben Ponvilawan ¹, Nipith Charoenngam ¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Bangkok, Thailand
Background/Purpose: Studies have suggested that primary hyperparathyroidism could be a risk factor for hyperuricemia although the results were inconsistent across the studies. This systematic review…
Abstract Number: 357 • 2019 ACR/ARP Annual Meeting
Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Andrew Shaffer¹, Elizabeth Rahn ², Kenneth Saag ², Amy Mudano ³ and Angelo Gaffo ², ¹University of Alabama at Birmingham, Vestavia, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham
Background/Purpose: Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based…
Abstract Number: 366 • 2019 ACR/ARP Annual Meeting
Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
Doo-Ho Lim¹, Gyung-Min Park ², Seung Won Choi ³, Su Jin Choi ⁴, So Hye Nam ⁵, Seokchan Hong ⁴, Yong-Gil Kim ⁴, Chang-Keun Lee ⁴ and Bin Yoo ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea, ²Ulsan University hospital, Ulsan, Republic of Korea, ³Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Ulsan, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ⁵Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: High serum uric acid (SUA) level is the main prerequisite for gout, and it might be associated with obesity, hypertension, glucose intolerance, insulin resistance,…
Abstract Number: 1215 • 2019 ACR/ARP Annual Meeting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Yanwei Lin¹, Xiaoxiang Chen ², Ping Ye ¹, Wenqin Geng ¹, Rui Ning ³, Yanfei Tai ³ and Chunde Bao ⁴, ¹Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ³Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Hyperuricemia, a common metabolic disorder, predisposes patients to develop gout due to the deposition of insoluble urate in joints. Safety concerns are frequently raised…
Abstract Number: 1219 • 2019 ACR/ARP Annual Meeting
Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
‪Gabriel Breuer‬‏¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: Hyperuricemia is associated with the development, progression and outcome of several diseases. The purpose of this study is to evaluate the serum uric acid…
Abstract Number: 1125 • 2018 ACR/ARHP Annual Meeting
Association between Hyperuricemia and Metabolic Syndrome with or without Obesity: Results from the 2016 Korea National Health and Nutrition Examination Survey
In Young Kim¹, Yeong Hee Eun¹, Eun-Jung Park², Joong Kyong Ahn³, Chan Hong Jeon⁴, Jaejoon Lee⁵, Hoon-Suk Cha¹, Eun-Mi Koh⁵, Kyungdo Han⁶ and Hyungjin Kim¹, ¹Department of Medicine, Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Division of Rheumatology, National Medical Center, Seoul, Korea, Republic of (South), ³Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Division of Rheumatology, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁶Department of Biostatistics, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Hyperuricemia is increasing worldwide, and is emerging as a potential biomarker and predictor for metabolic syndrome and related complications. We aimed this study to…
Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Sharon Dowell¹, Gail S. Kerr², Alvin F. Wells³, Richard Haddad⁴, Paul DeMarco⁵, Joyce Joseph⁶, Mercedes Quinones⁷, Shelby Hochberg⁸, Jennifer Ude⁹, Jim Huang¹⁰ and David Nashel⁶, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴The Hospital for Special Surgery, New York, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center, Washington, DC, ⁷Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center and Howard University, Washington, DC, ⁸Washington DC VA Medical Center and Howard University, Washinton, DC, ⁹Washington DC VA Medical Center and Howard University, Washington, DC, ¹⁰Medstar Health Research Institute, Hyattsville, MD
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…
Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Danica Grujic¹, Aditi Desphande¹, Robert Terkeltaub², Nadia Mosiichuk³, Kateryna Goncharva⁴ and Stefan Pirzynowski⁴, ¹R&D, Allena Pharmaceuticals, Newton, MA, ²VA San Diego Healthcare System, San Diego, CA, ³SGPlus and Lund University, Lund, Sweden, ⁴Lund University and SGPlus, Lund, Sweden
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…
Abstract Number: 2246 • 2018 ACR/ARHP Annual Meeting
Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis
David B. Mount¹, Tony R. Merriman² and Asim Mandal¹, ¹Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²University of Otago, Dunedin, New Zealand
Background/Purpose: Insulin plays a key role in the genesis of hyperuricemia. In particular, hyperinsulinemia in metabolic syndrome is inversely correlated with urinary uric acid (UA)…
Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].